Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 7, 2015, Pages 1155-1166

  Shah, Nina ^a   Callander, Natalie ^b   Ganguly, Siddhartha ^c   Gul, Zartash ^d   Hamadani, Mehdi ^e   Costa, Luciano ^f   Sengsayadeth, Salyka ^g   Abidi, Muneer ^h   Hari, Parameswaran ^e   Mohty, Mohamad ^i,w,x   Chen, Yi Bin ^j   Koreth, John ^k   Landau, Heather ^l   Lazarus, Hillard ^m   Leather, Helen ⁿ   Majhail, Navneet ^o   Nath, Rajneesh ^p   Osman, Keren ^q   Perales, Miguel Angel ^l   Schriber, Jeffrey ^r   Shaughnessy, Paul ^s   Vesole, David ^t   Vij, Ravi ^u   Wingard, John ^v   Giralt, Sergio ^l   Savani, Bipin N ^g   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h SPECTRUM HEALTH   (United States)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁿ HLL Communications   (United States)

^o LERNER RESEARCH INSTITUTE   (United States)

^p UNIVERSITY OF MASSACHUSETTS   (United States)

^q MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^r Virginia G Piper Cancer Center   (United States)

^s TEXAS TRANSPLANT INSTITUTE   (United States)

^t HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^u WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^w SORBONNE UNIVERSITÉ   (France)

^x CENTRE DE RECHERCHE SAINT ANTOINE   (France)

more..

Author keywords

Guidelines; Multiple myeloma; Recommendations; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; MYELOABLATIVE AGENT;

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL (TOPIC); COMORBIDITY; CYTOGENETICS; DISEASE COURSE; EVENT FREE SURVIVAL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAINTENANCE THERAPY; MEDICAL SOCIETY; MULTIPLE MYELOMA; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; THERAPY DELAY; TREATMENT RESPONSE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CHROMOSOME ABERRATION; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; GAMMA RADIATION; GENETICS; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPEUTIC USE; TIME FACTOR; TRANSPLANTATION CONDITIONING;

AGE FACTORS; CHROMOSOME ABERRATIONS; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; GAMMA RAYS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84930577739     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.03.002     Document Type: Review

References (133)

1. Kumar S.K., Dispenzieri A., Lacy M.Q., et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014, 28:1122-1128.
2. McCarthy P.L., Hahn T., Hassebroek A., et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013, 19:1116-1123.
3. Jones R., Nieto Y., Rizzo J.D., et al. The evolution of the evidence-based review: evaluating the science enhances the art of medicine-statement of the steering committee for evidence-based reviews of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2005, 11:819-822.
4. Harbour R., Miller J. Anew system for grading recommendations in evidence based guidelines. BMJ 2001, 323:334-336.
5. Attal M., Harousseau J.L., Stoppa A.M., et al. Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. NEngl J Med 1996, 335:91-97.
6. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. NEngl J Med 2003, 348:1875-1883.
7. Blade J., Rosinol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106:3755-3759.
8. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. JClin Oncol 2005, 23:9227-9233.
9. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004, 104:3052-3057.
10. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. JClin Oncol 2006, 24:929-936.
11. Palumbo A., Cavallo F., Gay F., et al. Autologous transplantation and maintenance therapy in multiple myeloma. NEngl J Med 2014, 371:895-905.
12. Koreth J., Cutler C.S., Djulbegovic B., et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007, 13:183-196.
13. Kumar S.K., Lacy M.Q., Dispenzieri A., et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012, 118:1585-1592.
14. Dunavin N.C., Wei L., Elder P., et al. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma 2013, 54:1658-1664.
15. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
16. Breitkreutz I., Lokhorst H.M., Raab M.S., et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007, 21:1294-1299.
17. Kumar S., Giralt S., Stadtmauer E.A., et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide-, or bortezomib-containing regimens. Blood 2009, 114:1729-1735.
18. Giralt S., Costa L., Schriber J., et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014, 20:295-308.
19. Duong H.K., Savani B.N., Copelan E., et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014, 20:1262-1273.
20. Singhal S., Powles R., Sirohi B., et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002, 30:673-679.
21. Kumar S., Lacy M.Q., Dispenzieri A., et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004, 34:161-167.
22. Alexanian R., Weber D., Delasalle K., et al. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004, 34:229-234.
23. Rosinol L., Garcia-Sanz R., Lahuerta J.J., et al. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica 2012, 97:616-621.
24. Vij R., Kumar S., Zhang M.J., et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant 2015, 21:335-341.
25. Merz M., Neben K., Raab M.S., et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol 2014, 25:189-195.
26. Ozaki S., Harada T., Saitoh T., et al. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol 2014, 132:211-219.
27. Bashir Q., Shah N., Parmar S., et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 2012, 53:118-122.
28. Saad A., Mahindra A., Zhang M.J., et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2014, 20:402-408.e1.
29. Facon T., Avet-Loiseau H., Guillerm G., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001, 97:1566-1571.
30. Chang H., Sloan S., Li D., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004, 125:64-68.
31. Moreau P., Facon T., Leleu X., et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002, 100:1579-1583.
32. Chang H., Qi C., Yi Q.L., et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005, 105:358-360.
33. Chang H., Qi X., Jiang A., et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010, 45:117-121.
34. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
35. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
36. Neben K., Jauch A., Bertsch U., et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010, 95:1150-1157.
37. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002, 99:731-735.
38. Lahuerta J.J., Mateos M.V., Martinez-Lopez J., et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010, 95:1913-1920.
39. Fenk R., Schneider P., Kropff M., et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 2005, 130:588-594.
40. Vela-Ojeda J., Garcia-Ruiz-Esparza M.A., Padilla-Gonzalez Y., et al. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus i.v. melphalan. Ann Hematol 2007, 86:277-282.
41. Palumbo A., Bringhen S., Bruno B., et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010, 115:1873-1879.
42. Lonial S., Kaufman J., Tighiouart M., et al. Aphase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 2010, 16:5079-5086.
43. Sharma M., Khan H., Thall P.F., et al. Arandomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012, 118:2507-2515.
44. Bodge M.N., Reddy S., Thompson M.S., Savani B.N. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. Biol Blood Marrow Transplant 2014, 20:908-919.
45. Bubalo J., Carpenter P.A., Majhail N., et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant 2014, 20:600-616.
46. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. NEngl J Med 2003, 349:2495-2502.
47. Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. JClin Oncol 2007, 25:2434-2441.
48. Sonneveld P., van der Holt B., Segeren C.M., et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica 2007, 92:928-935.
49. Sonneveld P., Schmidt-Wolf I.G., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. JClin Oncol 2012, 30:2946-2955.
50. Corso A., Mangiacavalli S., Barbarano L., et al. Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 years. Cancer 2007, 109:2273-2278.
51. Byrne M., Wingard J.R., Moreb J.S. Continuous infusion cyclophosphamide and low-dose total body irradiation is a safe and effective conditioning regimen for autologous transplant in multiple myeloma. Transplant Proc 2013, 45:3361-3365.
52. Regelink J.C., van Roessel C.H., van Galen K.P., et al. Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma. JClin Oncol 2010, 28:e741-743. author reply e4-5.
53. Lahuerta J.J., Grande C., Martinez-Lopez J., et al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea phase II trial. Br J Haematol 2003, 120:296-303.
54. Hussein M.A., Bolejack V., Zonder J.A., et al. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). JClin Oncol 2009, 27:3510-3517.
55. Gay F., Magarotto V., Crippa C., et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood 2013, 122:1376-1383.
56. Cavo M., Di Raimondo F., Zamagni E., et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. JClin Oncol 2009, 27:5001-5007.
57. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
58. Zangari M., van Rhee F., Anaissie E., et al. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 2008, 141:433-444.
59. Nair B., van Rhee F., Shaughnessy J.D., et al. Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010, 115:4168-4173.
60. Usmani S.Z., Crowley J., Hoering A., et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured?. Leukemia 2013, 27:226-232.
61. Pineda-Roman M., Zangari M., Haessler J., et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008, 140:625-634.
62. Kumar A., Kharfan-Dabaja M.A., Glasmacher A., Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. JNatl Cancer Inst 2009, 101:100-106.
63. Naumann-Winter F., Greb A., Borchmann P., et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012, CD004626.
64. Cavo M., Salwender H., Rosinol L., et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase III European studies. Blood (ASH Annual Meeting Abstracts) 2013, 767.
65. Anderson KC, Bensinger W. NCCN guidelines on Response after Therapy/Follow-up and Surveillance ver 2.2014. NCCN Guidelines Multiple Myeloma.2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf.
66. Dimopoulos M., Kyle R., Fermand J.P., et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011, 117:4701-4705.
67. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23:3-9.
68. Chee C.E., Kumar S., Larson D.R., et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood 2009, 114:2617-2618.
69. Zamarin D., Giralt S., Landau H., et al. Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. Bone Marrow Transplant 2013, 48:419-424.
70. Walker R., Barlogie B., Haessler J., et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. JClin Oncol 2007, 25:1121-1128.
71. Zamagni E., Patriarca F., Nanni C., et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011, 118:5989-5995.
72. Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
73. Rawstron A.C., Child J.A., de Tute R.M., et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. JClin Oncol 2013, 31:2540-2547.
74. Paiva B., Vidriales M.B., Cervero J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
75. Rawstron A.C., Orfao A., Beksac M., et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008, 93:431-438.
76. Flanders A., Stetler-Stevenson M., Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 2013, 122:1088-1089.
77. Mellqvist U.H., Gimsing P., Hjertner O., et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013, 121:4647-4654.
78. Spencer A., Prince H.M., Roberts A.W., et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. JClin Oncol 2009, 27:1788-1793.
79. Cavo M., Pantani L., Petrucci M.T., et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012, 120:9-19.
80. Berenson J.R., Crowley J.J., Grogan T.M., et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002, 99:3163-3168.
81. Shustik C., Belch A., Robinson S., et al. Arandomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007, 136:203-211.
82. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001, 113:1020-1034. Myeloma Trialists' Collaborative Group.
83. Fritz E., Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000, 11:1427-1436.
84. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289-3294.
85. Maiolino A., Hungria V.T., Garnica M., et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol 2012, 87:948-952.
86. Stewart A.K., Trudel S., Bahlis N.J., et al. Arandomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 2013, 121:1517-1523.
87. Morgan G.J., Gregory W.M., Davies F.E., et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012, 119:7-15.
88. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366:1770-1781.
89. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366:1782-1791.
90. Ye X., Huang J., Pan Q., Li W. Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials. PloS One 2013, 8:e72635.
91. Morgan G.J., Davies F.E., Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
92. Terpos E., Morgan G., Dimopoulos M.A., et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. JClin Oncol 2013, 31:2347-2357.
93. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22:414-423.
94. Palumbo A., Cavo M., Bringhen S., et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. JClin Oncol 2011, 29:986-993.
95. Anderson K.C., Alsina M., Bensinger W., et al. Multiple myeloma. JNCCN 2011, 9:1146-1183.
96. Auner H.W., Szydlo R., Rone A., et al. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma 2013, 54:2200-2204.
97. Chow A.W., Lee C.H., Hiwase D.K., et al. Relapsed multiple myeloma: who benefits from salvage autografts?. Int Med J 2013, 43:156-161.
98. Gonsalves W.I., Gertz M.A., Lacy M.Q., et al. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant 2013, 48:568-573.
99. Lemieux E., Hulin C., Caillot D., et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant 2013, 19:445-449.
100. Michaelis L.C., Saad A., Zhong X., et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013, 19:760-766.
101. Jimenez-Zepeda V.H., Mikhael J., Winter A., et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012, 18:773-779.
102. Shah N., Ahmed F., Bashir Q., et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012, 118:3549-3555.
103. Blimark C., Veskovski L., Westin J., et al. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. Eur J Haematol 2011, 87:117-122.
104. Cook G., Liakopoulou E., Pearce R., et al. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011, 17:1638-1645.
105. Fenk R., Liese V., Neubauer F., et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011, 52:1455-1462.
106. Burzynski J.A., Toro J.J., Patel R.C., et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009, 50:1442-1447.
107. Olin R.L., Vogl D.T., Porter D.L., et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009, 43:417-422.
108. Elice F., Raimondi R., Tosetto A., et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006, 81:426-431.
109. Qazilbash M.H., Saliba R., De Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006, 106:1084-1089.
110. Cook G., Williams C., Brown J.M., et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:874-885.
111. Atanackovic D., Schilling G. Second autologous transplant as salvage therapy in multiple myeloma. Br J Haematol 2013, 163:565-572.
112. Gahrton G., Tura S., Ljungman P., et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. NEngl J Med 1991, 325:1267-1273.
113. Verdonck L.F., Lokhorst H.M., Dekker A.W., et al. Graft-versus-myeloma effect in two cases. Lancet 1996, 347:800-801.
114. Ringden O., Shrestha S., da Silva G.T., et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012, 47:831-837.
115. Bjorkstrand B., Iacobelli S., Hegenbart U., et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. JClin Oncol 2011, 29:3016-3022.
116. Gahrton G., Iacobelli S., Bjorkstrand B., et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013, 121:5055-5063.
117. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
118. Moreau P., Garban F., Attal M., et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008, 112:3914-3915.
119. Giaccone L., Storer B., Patriarca F., et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011, 117:6721-6727.
120. Bruno B., Rotta M., Patriarca F., et al. Acomparison of allografting with autografting for newly diagnosed myeloma. NEngl J Med 2007, 356:1110-1120.
121. Knop S., Liebisch P., Hebart H., et al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma - an interim analysis of the German DSMM V Trial. ASH Annual Meeting Abstracts. Blood 2009, 114:51.
122. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
123. Rosinol L., Perez-Simon J.A., Sureda A., et al. Aprospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
124. Armeson K.E., Hill E.G., Costa L.J. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013, 48:562-567.
125. Kharfan-Dabaja M.A., Hamadani M., Reljic T., et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. JHematol Oncol 2013, 6:2.
126. Freytes C.O., Vesole D.H., LeRademacher J., et al. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant 2014, 49:416-421.
127. Mehta J., Tricot G., Jagannath S., et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?. Bone Marrow Transplant 1998, 21:887-892.
128. Bashir Q., Khan H., Orlowski R.Z., et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012, 87:272-276.
129. Mahindra A., Kalaycio M.E., Vela-Ojeda J., et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012, 26:1091-1097.
130. Kneppers E., van der Holt B., Kersten M.J., et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011, 118:2413-2419.
131. Alsina M., Becker P.S., Zhong X., et al. Lenalidomide maintenance for high risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014, 20:1183-1189.
132. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, andmethotrexate for prophylaxis of graft-versus-host disease afterreduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
133. Vodanovic-Jankovic S., Hari P., Jacobs P., et al. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006, 107:827-834.